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Abstract
Background: Randomised controlled trials (RCTs) often fail to recruit sufficient participants, despite altruism being
cited as their motivation. Previous investigations of factors influencing participation decisions have been
methodologically limited. This study evaluated how women weigh up different motivations after initially expressing
altruism, and explored their understanding of a trial and its alternatives. The trial was the ‘Quality of Life after
Mastectomy and Breast Reconstruction’ (QUEST) trial.
Methods: Thirty-nine women participated in qualitative interviews 1 month post-surgery. Twenty-seven women
(10 trial decliners and 17 acceptors) who spontaneously mentioned ‘altruism’ were selected for thematic analysis.
Verbatim transcripts were coded independently by two researchers. Participants’ motivations to accept or decline
randomisation were cross-referenced with their understanding of the QUEST trials and the process of randomisation.
Results: The seven emerging themes were: (1) altruism expressed by acceptors and decliners; (2) overriding personal
needs in decliners; (3) pure altruism in acceptors; (4) ‘hypothetical altruism’ amongst acceptors; (5) weak altruism
amongst acceptors; (6) conditional altruism amongst acceptors; and (7) sense of duty to participate. Poor
understanding of the trial rationale and its implications was also evident.
Conclusions: Altruism was a motivating factor for participation in the QUEST randomised controlled trials where the
main outcomes comprised quality of life and allocated treatments comprised established surgical procedures.
Women’s decisions were influenced by their understanding of the trial. Both acceptors and decliners of the trial
expressed ‘altruism’, but most acceptors lacked an obvious treatment preference, hoped for personal benefits
regarding a treatment allocation, or did not articulate complete understanding of the trial.
Trial registration: QUEST A, ISRCTN38846532; Date assigned 6 January 2010.
QUEST B, ISRCTN92581226; Date assigned 6 January 2010.
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Background
Randomised controlled designs for trials of different treat-
ments (RCTs) are essential to minimise selection bias and
ensure that treatments are based on the best possible evi-
dence. However, many trials do not recruit the desired
participant numbers required to meet study objectives,
despite often citing altruism as their motivation for par-
ticipating. The statistical power of the results then be-
comes compromised or the costs through extensions to
the recruitment period are increased [1]. In order to maxi-
mise the rates of trial participation whilst ensuring pa-
tients can make their decisions based on a clear
understanding of what is involved, it is imperative to
understand factors affecting motivation and patient deci-
sions around participation and non-participation in trials.
Altruism, defined as ‘acting with an unselfish regard
for others’ , has been identified as a potentially important
factor in patient’s decision-making as to whether or not
to consent to trials. Altruistic motivations in healthcare
trials include patients’ desire to help others with the
same condition and contribute to progressing medical
knowledge [2]. However, factors other than altruism may
be motivating factors in patients’ decisions; although
cancer trial participants within drug-intervention studies
commonly reported that altruism contributed to their
decision to enrol, they also expected to receive medical
benefits [2–4].
Current studies evaluating the levels of trial participa-
tion are methodologically limited; involving either
healthy participants responding to hypothetical scenarios
in analogue studies; and by focusing exclusively on those
patients consenting whilst ignoring those who de-
clined [5]. Previous surveys are difficult to interpret
as respondents were rarely asked to make a choice
between self-interest and altruism, typically reporting
both motivations without exploring how these motiva-
tions were weighted [4].
Importantly, regulation of most new drugs and devices
mean that they are available to patients only if they agree
to participate in a clinical trial, making it difficult to disen-
tangle their motivations toward science and themselves.
Many agree to participate in the hope of receiving experi-
mental treatment as well as contributing to medical know-
ledge. Different trial designs include control arms which
could be a standard treatment or a placebo (even sham
surgery in some cases), which compound the difficulty in
interpreting results about motivation. [6, 7]. Recently,
McCann et al. [8] conducted a qualitative study, embed-
ded in a ‘patient-preference’ trial (in which patients could
either select their preferred treatment or accept random
allocation of those treatments). Results suggested that
people rarely participate in trials out of purely altruistic
reasons, and often require some perceived personal bene-
fit from being randomised in a trial.
Our study investigates what is often regarded as a so-
cially desirable, yet unexplored, response of altruism. To
better understand how patients weigh altruism in their
decision-making about participating in clinical trials we
also examined any stated personal treatment preferences
and understanding of fundamental aspects of RCTs,
such as randomisation and clinical equipoise. The effects
of altruistic motivations on decisions about participation
might be moderated by misperceptions of randomisa-
tion, equipoise or by treatment preferences [7]. For ex-
ample, patients may be motivated to participate because
they believe that the research will benefit others but de-
cide against taking part because they have not under-
stood the attributes of an RCT. On the other hand, a
decision to participate in the trial might seem to be
purely altruistic if the patient has a strong personal
treatment preference and their decision to participate in
the trial is made with a full understanding that, through
randomisation, they may not receive the preferred treat-
ment that they could have selected outside the trial.
The Quality of Life after Mastectomy and Breast Recon-
struction (QUEST) trials (Cancer Research UK funded:
C10318/A10077, reference Trial A ISRCTN: 38846532,
Trial B 92581226) comprised two parallel feasibility phase
III randomised multicentre trials to assess the impact of
the type and timing of latissimus dorsi (LD) breast recon-
struction on health-related quality of life (HRQL) when
post-mastectomy radiotherapy is unlikely (Trial A) or
highly probable (Trial B) [9]. All women with either inva-
sive breast cancer or ductal carcinoma in situ requiring
mastectomy were eligible (Fig. 1) [9]. Surgical treatment
arms comprised a standard care arm versus a less prac-
ticed new intervention arm in both trials. The standard of
care was implant-assisted LD breast reconstruction in
Trial A, and staged-delayed (two-stage) extended autolo-
gous LD breast reconstruction in Trial B. Despite its prag-
matic design, the LD breast reconstruction techniques
were well established in the UK, and were potentially
available to patients outside the trial.
The QUEST Perspectives Study (QPS) was an embed-
ded study evaluating the perceptions of patients and
healthcare professionals on randomisation (views on
decision-making and subsequent experiences) to inform
QUEST trial processes and enhance ongoing recruitment
and patient acceptability. In the current analysis, we ex-
amined patients’ views about altruism, as a factor in their
decision to participate (or not) in a clinical trial, in the
context of: (1) their understanding of randomisation (the
rationale and trial process); (2) their comprehension of
clinical equipoise related to the impact of health-related
quality of life (HRQL) on the types and timings of imme-
diate LD breast reconstruction; and (3) their perceptions
of and preferences towards the treatment options available
to them both before and after randomisation.
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Methods
Recruitment and procedure
QUEST and QPS were each approved by South West
Exeter Health Research Authority (QUEST Trial A 10/
H0206/41, QUEST Trial B 10/H0206/42) [9]. Eligible
patients approached to participate in QUEST were sim-
ultaneously invited (face to face) to participate in QPS.
Informed consent was gained from all participants for
both the QUEST trials and QPS. The women who con-
sented to the QPS comprised both decliners and accep-
tors of QUEST. They were invited to participate in a
semi-structured telephone interview 1 month after their
breast reconstruction surgery with one of the researchers
(NB or LM, both experienced qualitative researchers in
behavioural medicine and independent from the re-
search team conducting the QUEST trials). Interviews
were audio-recorded with participants’ permission and
transcribed verbatim. The interviews explored the
women’s understanding of the QUEST trials, the process
of randomisation and their perception of the surgical op-
tions. The interviews also explored patients’ decision-
making processes in accepting or declining to enter
QUEST and the factors they considered when making
the decision including their eventual motivations influ-
encing their decision.
One hundred and twenty-four patients were eligible to
enter QPS, and 56 (45 %) consented, of whom 39 took
part in qualitative interviews [9]. Reasons for consenting
to, but not completing, the interviews included the fol-
lowing: researchers were unable to contact the partici-
pant after multiple attempts and changes in participants’
personal circumstances making interviews inappropriate.
The analysis presented here focuses on those interviews
in which participants spontaneously raised ‘altruistic’
motivations to explore the meaning and types of genuine
sentiment or socially desirable answers (n = 27). The
demographic characteristics of this subset of the inter-
viewees are summarised in Table 1.
Data analysis
Two authors (NB and LM) initially independently coded
the transcripts using NVivo 10 software. Using the
grounded theory approach, thematic analysis enabled
codes to be conceptualised into common themes [10].
Emerging themes were subsequently discussed with and
guided by SE (an experienced bioethicist and qualitative
researcher in research ethics and independent from the
QUEST trial research team). The themes were further de-
veloped by NB and LM using the original interview tran-
scripts. After independent coding, consensus agreement
Fig. 1 Randomisation in the QUEST trials
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was reached through discussion where initial coding dif-
fered. Participants’ expressed motivations to accept or de-
cline the trial were the key finding.
To explore the inter-relationships between these fac-
tors, the expressed altruism was cross-referenced with
other expressed motivations, and with understanding of
the trial, of randomisation, and of alternative treatment
options (as judged independently and agreed by NB and
LM), as well as with their actual decision. Patients’ over-
all understanding was assessed independently by draw-
ing on different aspects of the transcripts (NB and LM)
and noting consistency of responses with known conse-
quences of their actual decisions for treatment alloca-
tion. (A participant stating a treatment preference with
self-interested motivation, but accepting randomisation,
may have misunderstood information about the trial). A
full analysis of understanding will be reported elsewhere.
Additional findings from QPS, other than the spectrum
of altruistic motivations are presented elsewhere [9, 11].
The themes regarding expressed altruism are pre-
sented below with illustrative quotes from participants.
Results
Altruism was initially expressed by both acceptors and
decliners
Altruistic motivations were initially expressed both by
women who accepted and declined the QUEST trials.
They expressed a desire to help the investigators and to
improve care for women with breast cancer in the fu-
ture. In some cases, the altruistic decision to participate
in the trial seemed to be taken with an understanding of
trial processes and the desire to help others after receiv-
ing a life-changing diagnosis. Those who declined par-
ticipation, however, also reported strong beliefs in the
value and importance of research and of helping people
(Table 2).
Not all the women expressing altruistic motivations
were able to articulate full understanding of the rationale
for and process of randomisation, and therefore their de-
cision whether or not to take part could not be seen as
fully informed (Table 2, participant 22).
The initial expression of altruism therefore did not
seem to differentiate between decliners and acceptors.
Some of those who declined to participate yet
expressed altruistic intentions did not fully under-
stand what randomisation involved. However, partici-
pants’ discourse often revealed other motivating
factors beyond the initial desire ‘to help others’ by
taking part in QUEST. These cause us to question
whether those who declined would have reached a
different decision had they had a better understanding
of randomisation. The factors influencing the eventual
decisions by decliners and acceptors are described in
the following themes.
Personal needs took precedence in decliners
Other factors overrode the altruistic motivations initially
expressed by those who declined. For most decliners,
their own current needs took priority over any altruistic
inclinations and, although they were interested in help-
ing other people and accepted the importance of re-
search (with many fully understanding both the rationale
for and process of randomisation), they felt that, at this
time, it was more important to focus on themselves and
what was right for them (Table 3, participant 19).
While accepting the potential benefits of the trial to
others, some women who declined to take part did so
because they not only failed to see any personal advan-
tage in participating, but also perceived randomisation
to be detrimental to their individual needs (Table 3, par-
ticipant 27).
Alternatively and despite there being clinical equipoise
between the options offered in the QUEST trials, some
decliners retained a belief that one option was better for
them than the other and therefore held a treatment pref-
erence that eventually guided their decision. However,
they did not fully understand the process of randomisa-
tion, which may have been too daunting, or they seemed
to want to avoid one or other of the trial treatments
(Table 3, participant 16).
Table 1 Demographics of interviewees included in current
analysis
QUEST
acceptors
(n = 17)
QUEST
decliners
(n = 10)
Total
(n = 27)
Age, mean (sd) 53.2 (9.28) 54.7 (10.22) 53.7 (9.37)
Ethnicity
White British 15 10 25
White Irish 1 0 1
Black African 1 0 1
Education, n (%)
Degree 8 (47) 5 (50) 13 (48)
Continued after
minimum school-
leaving age
2 (12) 3 (30) 5 (19)
Did not continue after
minimum school-
leaving age
7 (41) 2 (20) 9 (33)
Marital status, n (%)
Single 3 (18) 0 3 (11)
Married/living together 13 (76) 6 (60) 19 (70)
Separated/divorced 1 (6) 3 (30) 4 (15)
Widowed 0 (0) 1(10) 1 (4)
Dependent children,
n (%)
9 (53) 3 (30) 12 (44)
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Pure altruism (true selflessness) in an acceptor
Many acceptors also held treatment preferences going
into the trial. Only in one case was an acceptor not allo-
cated her expressed preference during randomisation.
This lady accepted randomisation regardless, apparently
demonstrating pure altruism. Her immediate preference
was to have the surgery completed as quickly as possible
in order to progress with her life. However, from her ex-
planation it was clear that although she discussed a com-
puter deciding the surgical option, she also referred to
the doctors choosing the option and that they were
likely to know which was better due to their experience,
and therefore their decision would ultimately be better
than her own decision. Therefore her understanding of
randomisation was inaccurate (Table 4).
‘Hypothetical altruism’ (selfless behaviour stated but not
put to the test) amongst acceptors
Of those acceptors with treatment preferences who were
allocated to them during randomisation, most stated that
they would have accepted the alternative had they been
allocated to it, despite being able to withdraw after ran-
domisation and select their preferred treatment, therefore
demonstrating, hypothetically, a high commitment to the
trial. We have therefore labelled this as ‘hypothetical
altruism’.
Some participants who were allocated to their treat-
ment preference, but claimed that they would have
Table 2 Altruism expressed by acceptors and decliners
[On altruism] My reaction was if this is going to help other people who’ve
got cancer I’m happy to do that, my primary thought. I think it depends
on one’s personality and character as to would view in other people but I
really like to do that so my main thing wasn’t actually of me, it was
helping other people because it was such a shock when I found out I’d got
it [breast cancer]. It was so shocking. I had no idea, not a smoker, not a
drinker or anything. I was just so shocked and I thought, ‘Gosh if any
information they can glean from me is going to help people’.
[On randomisation]…obviously because of them randomising it, it’s
neutral, isn’t it in a way. Whereas if one makes the choice people might
always go for a certain option which then makes it a bit more
complicated… I presume it’s [randomisation] giving more of a balanced
view of what treatments are administered so that you can get a clearer
picture of what the benefits are and facts and things like that.
Trial acceptor, full understanding of randomisation (participant 7)
[On altruism] I wasn’t thinking of it so much for myself [potential trial
benefits] but I think any diagnosis of a major illness changes your outlook
anyway and it is such a life-changing thing that anything that I felt I could
do to contribute to things being better for anyone in the future I just
thought it was a good opportunity to do that and it wasn’t anything that
was going to jeopardise my treatment or any outcome for me in any way
but at least I thought it wouldn’t.
[On randomisation]…the computer would choose which option and it
was because that’s the fairest way to do the research so it’s not sort of
weighted by any other considerations..
Trial acceptor, full understanding of randomisation (participant 8)
[On altruism] For me, initially taking part in trials, it was simply that I
worked in clinical trials and obviously working in it, it’s something I believe
in and it was something I wanted to help with so for me that was why I
wanted to be involved in some of them.
[On randomisation] [Researchers used randomisation] So that the
conclusions that you draw at the end of it are not influenced by any
preconceived ideas from the knowledge of which streams you are
randomised into.
Trial decliner, full understanding of randomisation (participant 25)
[On altruism] Well to be honest I didn’t mind because I thought if it helps
other people that I didn’t mind and I thought I agreed to take part in
another study where they were taking my blood as well and stuff.
[On randomisation] I was aware that the computer, this is how I was
made to think it was whether it was right or wrong, that the computer
would decide on my surgery. And I was kind of like ooh how… it doesn’t
know me, do you know what I mean? Obviously, in retrospect, thinking
about it all the relevant information would have been inputted into that
computer, I know that now, but at the time it was no, it’s not a person.
[…] it wasn’t explained to me if I could disagree with the computer.
Trial decliner, did not fully understand randomisation (participant 22)
Table 3 Personal needs taking precedence
[Own need] I don’t know, it’s just my personality thing, I’m just aware that
research needs to be done, […] and I just thought ‘Oh God I ought to do
it’ and then I thought ‘No, absolutely not, it’s not for me’. […] to be honest
it’s the control thing because when you’re diagnosed you just feel like your
life’s on hold. People are saying, ‘Can you come and do this that and the
other,’ and you think, ‘Well I don’t know. I don’t know when my operation is
going to be. I don’t know when the tests are going to be. I don’t even
know if I’ll be able to go out at work or what.’ You’ve got no control over
anything. Then to not even have any control over the process, the
procedure it just seemed like yet another decision that I didn’t have really.
[On randomisation] That if I was happy to either have an implant, or not
and then it would be randomly decided whether I would get one or not.
[…] what happens is that your name goes in a hat more or less. […] it’s
just because it makes it completely fair […]
Trial decliner, full understanding of randomisation (participant 19)
[Own need] I’m the kind of the person that’s happy to try to do things. I
was a blood donor for years. I’m happy to do it voluntarily but it’s not so
much that when you’re given the information you are always thinking, it
sounds selfish, but, ‘What will I get out of this?’ As much as, ‘What can I
give to them?’ It’s nice if you can get a little bit out of it for yourself […]
[On randomisation] It’s like being in a lottery, isn’t it? […] When you’re in
hospital you want to feel that you’re not being treated as a lottery number,
you’re being treated as an individual. It’s important because then you feel
that your best interests are at heart […] doing something randomly you
haven’t got the researchers, they’re not choosing which patients to use it’s
the randomisation so therefore you can be going from a wider spectrum of
people instead of thinking, ‘Oh well I’m going to do this study and I’ll just
pick out blonde-haired blue-eyed 30-year-olds,’ or, ‘I’ll pick her because I like
the colour of her hair.’ You’ve got no input at all as to why you’re picking
somebody. It’s completely random and that, to me, is for a study I can
understand it, but as a patient you don’t like to feel you’re in a lottery.
Trial decliner, did not fully understand randomisation (participant 27)
[Own need and randomisation] I didn’t mind being asked, I was quite
happy to go into the trial for that reason, because it’s research and it’s
proving a point and hopefully all for the benefit of mankind, that didn’t
worry me. Randomised I didn’t think I really understood what they meant
by randomised until it was explained to me that you get whatever
treatment we give you type thing, as in the different flaps that are on offer
for rebuilding your boob and all that jazz. But as soon as they said implant
I baulked at implant because I didn’t want an implant.
Trial decliner, understood rationale for but not process of randomisation
(participant 16)
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accepted the alternative fully comprehended the process
of and rationale for randomisation (Table 5). However,
one participant (participant 13) also expressed complete
trust in her healthcare team and a certain belief in the
‘equivalence’ of the treatment options (as if there were
evidence that the options were equally good rather than
that there was currently no evidence of differences in
HRQL), which could have indicated a misunderstanding
about clinical equipoise and hence a therapeutic miscon-
ception associated with the trial.
Most ‘hypothetical altruists’ did not demonstrate a full
understanding of randomisation and may not have fully
appreciated the consequences of remaining in the trial
and on a treatment they did not prefer (Table 6). An-
other acceptor (participant 12) thought that the trial co-
ordinators decided on her allocation based on her
clinical information. She was happy to accept either op-
tion despite a preference for no implant as she trusted
the surgeon’s advice that she was suitable for both
options.
Weak altruism amongst acceptors
Some acceptors did not have a treatment preference go-
ing into the trial and therefore demonstrated what could
be described as a ‘weak’ form of altruism since there was
an absence of personal benefit rather than an active
intention to benefit others. Some of these participants
had full understanding of randomisation and so their al-
truistic motivations were based on the knowledge that
they could have been assigned to either treatment at
random (Table 7).
Conditional altruism (selflessness dependent on
perceived personal benefits) amongst acceptors
For some acceptors, their altruistic behaviour ap-
peared to be contingent on perceived immediate per-
sonal benefits from taking part in the trial, recognised
elsewhere and termed conditional altruism [8].
Expanding on the weak altruism presented above, for
some women, not having to choose was a direct
benefit of participating in the trial. They reported that
decision-making was extremely difficult either because
they had no preference or because they were over-
whelmed by their diagnosis and the quantity of
information. The first participant demonstrated full
understanding of randomisation, the second under-
stood the rationale, but did not articulate an under-
standing of how it was conducted (Table 8).
One acceptor regarded consenting to randomisation as
a way of regaining personal control over her diagnosis
(Table 9, participant 5). She demonstrated full under-
standing of randomisation and was in clinical equipoise
as illustrated in the weak altruism theme above. Another
perceived advantage for participants was that they felt
they would gain more attention and be better listened to
as part of the trial (Table 9). No such benefits were
highlighted to participants during the recruitment
process, yet participants could have perceived the
Table 4 Pure altruism
[On her preference] I said okay I want to finish this and get out of this
mess. Sometimes that’s how I say things because that’s how I think, not
say it, but that’s how I think. So as a patient you always feel to finish
it quickly and just go on with your life. It doesn’t work like that. The
doctors know more about us, about what we are going through than
ourselves. […]
[On randomisation] The computer makes the decision I say okay I don’t
make too much like oh no I just say this is what I want, I don’t want to go
to implant thingy but if that’s what they choose, the doctors know more
than me so I will go ahead with the decision. […] Yes and they [doctors]
said because in my case because they know what they are saying and they
know what happens I don’t know. So if they say this is the best for you so I
will go ahead with that.
Trial acceptor, did not fully understand randomisation (participant 9)
Table 5 Hypothetical altruists with trial understanding
[Preference] Was to have as much surgery done in one go really to be
honest […] because from being diagnosed, the whole treatment pathway
it’s really lengthy, everyone can appreciate that. In my mind delaying the
reconstruction would have just lengthened that even more […] From what
I remember, I could’ve pulled out at any time from the trial anyway. I
wouldn’t have wanted to and I don’t think I would have done, but I was
fully aware that I could pull out at any time which was fair and I did
appreciate that.
[On randomisation]…people can be put into a system and you were
randomly picked [for different surgical options] from what I believe…. It
makes it a little bit more fair doesn’t it? Hopefully you get a completely
different cross-section of ladies taking part, following each process really,
but you’re not getting say for example, all the ladies my age doing it one
way and then all the ladies of an older age doing it the other way, then of
course it’s not a fair representation is it of everybody involved.
Trial acceptor, full understanding of randomisation (participant 15)
Participant: I was told from very early on if you have a strong view and it
comes back with what you don’t want you can opt out of the trial at any
time […] I didn’t want an implant because I looked further into possible
post-op complications and things and when it came back it was a non-
implant so that was fine. I actually in the couple of days, because I went, I
think it was the Thursday, and they put me in for the trial and then the
randomisation came back on the Monday, so over the weekend I was
thinking please don’t let it be an implant, please don’t let it be an implant.
Anyway it came back and it wasn’t an implant so that was fine.
Interviewer: What do you think you would have done if it had come back
with the other option?
Participant: I probably would have gone with it anyway because I
absolutely trust the team that are looking after me. I think that was the
most important thing that you trust the team that are caring for you and
my surgeon was absolutely adamant that both outcomes would be as
good.
[On randomisation] In order to be able to be on the trial I had to be
suitable for either a reconstruction with an implant or without an implant
… and the randomisation happened in that no one person decided, a
computer spit it out or somebody spit it out and it meant that it wasn’t
down to my choice […] Nobody chose, it was a computer or a person
picking a name out of a hat that chose rather than the surgeon and stuff
so that meant that my experience wasn’t influenced by anybody.
Trial acceptor, full understanding of randomisation (participant 13)
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additional contact time as being beneficial. In addition,
the focus of the trial was quality of life outcomes after
surgery, and therefore participants may have perceived
that in participating there may be an increased emphasis
on this. However, as illustrated by participants’ quotes in
the themes previously discussed, these participants
understood that the best surgical option for them was
decided upon through their clinical information. Both
expressed a preference for their surgery but would have
been happy to accept the alternative due to their belief
in the surgeon’s view that the other option was equally
suitable for them clinically.
Sense of duty to take part
Some acceptors reported participating in the trial out of
a sense of duty instead of expressing straightforward al-
truistic motivations in their reasons for wanting to take
part (Table 10). They felt that by taking part they would
be able to ‘pay back’ for all the treatment they had re-
ceived and for the contributions that women before
them had made to enable them to have the treatment
they had. While most of these women had full under-
standing of randomisation as in the two quotes below,
some did not and this misperception was that the most
suitable treatment option would be selected based on
Table 6 Hypothetical altruists without full trial understanding
Participant:[…] It wouldn’t make no difference about the trials, if I was
randomised for a different type and I didn’t like it, she [the nurse] said
that’s no problem, she said you don’t have to go on the trials but I agreed
in the end. I thought about it and I agreed. I thought yes it’s a better
outcome and for people to understand more about breast cancer.
Interviewer: So how do you think you would have felt if you would have
been randomised just to have no implant [less preferred option]?
Participant: I wouldn’t have minded. I think after going through the
operation and going through the cancer, I didn’t mind either way as long
as the cancer was gone and I was a shape, I was still a woman with my
own flesh there somewhere […]
[On randomisation] I thought that the computer put in my details and
then have a look through it all and see what is best for me and when I
thought about it afterwards they said I could change my mind at any
time, I didn’t have to go through with what the computer picked but
thinking about it, and I thought yes I think I would like to go along with it.
Trial acceptor, did not fully understand randomisation (participant 11)
Interviewer: So knowing that you had this preference not to have an
implant, how did you feel about being randomised then, knowing that you
might have been offered the other option?
Participant: Well, after speaking to [surgeon], he did say that both,
whichever one they decided to do, and I trust that man absolutely, that it
would be perfect for me.
Interviewer: So if you had been randomised to have an implant, you
would have been happy to go along with that?
Participant: Yes.
[On randomisation] I think they [the Quest people] just looked at
everything, what I was like, all my notes and everything and then decided.
[…] Well, the Quest people. […] This is how I understood it, they wanted
equal amounts of women to go for and against the two procedures.
Trial acceptor, did not fully understand randomisation (participant 12)
Table 7 Weak altruism
[On randomisation and no preference] […] if you were suitable, you
could be randomised, i.e. the computer would decide which operation you
were having and the outcomes were both, I was explained that there were
pros and cons to both and I was happy to have both of the surgeries and
actually it was quite nice for me because I don’t think I could have decided
[…] obviously on the […] study makes it fairer. If they’d picked me to do
something, it could’ve been for a reason, it could’ve been for something I
said whereas letting a computer decide is completely random and it
chooses what it likes based on nothing whatsoever.
Trial acceptor, full understanding of randomisation (participant 5)
Table 8 Conditional altruism
[Choice made] […] as I say it’s the least I can do and also I feel quite
chosen to be one and it’s helped me which you know I don’t know
whether with QUEST when you set it up thought, oh they might feel a little
comfort from this; my comfort is that I didn’t have to decide what I was
having at a time when I was making decisions.
[On randomisation] I know that that was okay and I could understand
why they said you can’t choose the computer has to choose for you and I
could see that, because you wouldn’t get the fair result would you if we all
started to say “we’ve got to choose one”.
Trial acceptor, full understanding of randomisation (participant 1)
[Choice made] I think it was just having the choice made for me and as I
say I thought well if any data or research that would be useful that would
come out of it then if it helps other people later on down the line then I
am quite happy to do that.
[On randomisation] I think they are obviously trying to find which surgery
is best for most people […] if you are in the position where you have got
two options of surgery I think they are obviously, I thought they were trying
to find out which was really best for patients in the long run, collecting
data on the two different procedures because I suppose if a surgeon is
choosing or a patient is choosing you could only get one type of surgery
being done far more than the other and perhaps they want to find out,
make it something a bit fairer really and see how patients respond to the
different types of operation and surgery.
Trial acceptor, understood rationale for but not process of
randomisation (participant 2)
Table 9 Perceived trial benefits or advantages
It was a positive for me, it was something I could do that was a positive
from it all basically. I think lots of things that happen to you when you’re
having surgery and going through this procedure, you’ve got no control
over, but actually I could choose what I wanted to do. I could feel that
there was some positive coming out of it whatever the outcome was for
me, which was quite nice.
Trial acceptor, full understanding of randomisation (participant 5)
Yes, I do actually because, like yourself ringing me now, because I thought
someone would ring in a month and then three and so on. You're getting
to know how I'm feeling to help other people. And, also, you're keeping
checks on how we're doing which I think is a brilliant thing, more so than
if I wasn't doing the QUEST.
Trial acceptor, did not fully understand randomisation (participant 12)
I thought I’d get the best care because they’re [QUEST investigators] really
interested in what you’ve got to say and how you feel and I thought well,
this way and also that other women could benefit by it as well.
Trial acceptor, did not fully understand randomisation (participant 11)
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their clinical information. Consequently, they did not
perceive any personal sacrifice through participating in
research. Two women who indicated this ‘sense of duty’
to participate had clear treatment preferences, but
nevertheless consented to randomisation. One was allo-
cated her preference and one was not and both indicated
that they would have accepted the alternative as de-
scribed in the previous sections.
Discussion
This study explores the meaning of expressed altruism
when patients are invited to participate in a surgical
RCT where the primary outcome measure comprised
HRQL and where the new surgical interventions were
available outside the trial. This study illustrates how pa-
tients weighed up different motivations, after initially ex-
pressing altruism, to decide whether or not to accept the
trial, and reports how informed those motivations were,
given the patients’ understanding of the trial and the
treatment options available, and any stated personal
preferences.
Altruism was expressed initially by both acceptors and
decliners of the QUEST trials. These initial motivations
were often modified by understanding the trial and indi-
vidual beliefs about the surgical options, and, in many
cases, were overridden by personal interest according to
treatment preference. Moreover, some acceptors who
were in ‘clinical equipoise’ seemed simply not to mind
being randomised. Altruism was still expressed by some
who had accepted randomisation despite having a treat-
ment preference. All but one of these patients were ran-
domly allocated to their treatment preference and so did
not have to ‘test’ their declared altruism afterwards by
potentially withdrawing after randomisation.
Our findings somewhat corroborate results from a re-
cent qualitative study suggesting that altruistic motiva-
tions amongst those who accept randomisation are often
tempered by self-interested motivations in various ways
even when they are in a state of clinical equipoise [8].
However, it was unclear how informed these motivations
were. Some patients perceived benefits of taking part in
the QUEST trials, such as avoidance of making a diffi-
cult choice between surgical options, gaining an element
of control by deciding to participate or perceived greater
input from the healthcare team, and their altruistic moti-
vations were conditional upon this. There is some, albeit
weak evidence from comparative studies suggesting that
patients may do better within trials on similar treatment
to those outside of trials [12]. This study further ex-
plores conditional altruistic motivations by cross-
referencing the patient's declared motivations with their
actual decisions and their understanding of the trial.
Only one patient in our study consented against her de-
clared treatment preference, but she did not fully under-
stand the trial and it was unclear whether her decision
to take part was an authentic choice to be altruistic (i.e.
one that reflects the true preference of the individual).
Our finding that patients did not always fully under-
stand the trial and its alternatives (both acceptors and
decliners) concurs with previous work [13]. There ap-
peared to be misunderstanding of how the treatment op-
tion was decided if they entered the trial and, related to
this, some participants did not hold views consistent
with ‘clinical equipoise’. For decliners, misunderstanding
randomisation and equipoise may not be the sole factors
responsible for them choosing not to take part as they
had strong preferences for a particular surgical option or
they wished to make the decision by having control
themselves. Findings from this study were regularly re-
ported to the QUEST Trial Management group and the
Trial Steering and Data Monitoring Committee whilst
the trials were running, and helped inform ongoing
recruitment strategies. A standardised trial informa-
tion checklist was an early by-product of this study
3 months after trial commencement. The use of this
checklist by the research nurse within trial consulta-
tions was standardised across all centres and was in-
strumental in attempting to balance expressed patient
preferences [9].
We did not include all those respondents in QPS
(namely those who did not express any altruism) in our
present analysis because there would have been no way
of weighing up different motivating factors in the unique
way QUEST allowed. While an expression of self-
interest alone does not necessarily exclude all altruistic
motivation, we were primarily interested in those situa-
tions in which self-interest and altruism led to contra-
dictory decisions to help gauge the strength of those
motivations.
The challenges of surgical trials are well described by
Cook et al. (2015) with recommended trial designs in-
cluding a feasibility phase and embedding qualitative re-
search to inform trial processes [14]. As the first
multicentre trials in this setting, the QUEST feasibility
trials showed overall patient acceptability rates of 19 %
(17 out of 88) in Trial A and 22 % (8 out of 36) in Trial
B, respectively over 18 months of recruitment [9].
Table 10 Sense of duty
It seemed quite straightforward so they [healthcare team] were very, very
good at the whole thing, and I just thought well, this is the least I can do
you know, it wasn’t hard to decide.
Trial acceptor, full understanding of randomisation (participant 1)
They’re important really [trials] because my treatment from start to finish
has been influenced by other ladies going through similar trials, for all sorts
of different reasons. Really, it was me putting my little bit back in for
women in the future to be honest.
Trial acceptor, full understanding of randomisation (participant 15)
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The findings from this study should be considered in
light of its limitations. The interviews were conducted
after surgery, and at least a month after the women had
made the decision whether or not to accept randomisa-
tion. In addition to potential difficulties with accurate re-
call, it is possible that initial preferences and perceptions
were modified as a result of the outcome of randomisa-
tion (for acceptors) and post-surgery experiences. Fur-
thermore, the QUEST trials were surgical RCTs,
comparing the impact on HRQL of different types and
timing of LD breast reconstruction. In addition, the
treatments offered in the trial, while available outside
the trial, may not always have been offered to patients
making the trial a ‘quasi-preference’ trial. The findings
from the current study may not be generalizable to other
RCTs attempting to recruit from different patient popu-
lations, or to evaluate the efficacy of a novel drug treat-
ment against either an active or placebo control, and
under different conditions.
Nevertheless, the knowledge gained from this study
provides valuable insight that can inform and refine at-
tempts to recruit participants to future RCTs. In particu-
lar, information given to patients at the time of consent
should clarify the potential benefits of trial participation.
The dedicated trial consultation should be led by non-
biased healthcare professionals using standardised in-
formed consent where iteration of pros and cons may
change/balance patient preferences and perceptions.
Evaluation of the patient’s understanding of information
as this pertains to randomisation should be routinely
assessed to ensure that any expressed altruism is based
on truly informed consent. In addition, more research is
needed in this area to explore the limits to conditional
altruism once patient understanding of trials has been
improved in practice. For example, it is not yet clear
how perceiving beneficiaries of the trial influences feelings
of altruism. Currently, patients are often simply told -
vaguely - that the trials to which they are invited to
participate in, are designed to benefit patients in the fu-
ture. This futuristic expectation risks undermining the
fundamental precepts of good informed consent, where
the patients’ understanding of the rationale and benefits of
trial participation are key goals in current trial recruit-
ment. Recommended testing of patient’s understanding of
informed consent should be an integral part of feasibility
and pilot phase studies within RCTs.
Conclusions
This study makes a valuable and unique contribution to
the understanding of the factors influencing patients’ deci-
sion whether or not to enter a surgical RCT where the
treatment options may be preference-sensitive, despite
being technically established and poorly evidenced in
terms of patient-reported HRQL. By employing qualitative
methods and thereby avoiding some of the limitations of
previous research in this area, we have highlighted how
different motivations, including altruism, were evaluated
by the participants in the context of their understanding
of the trial and randomisation. Although both acceptors
and decliners of the QUEST trials initially expressed altru-
istic motivations, these were often revised or outweighed
by other factors related to the participants’ own interests
and perceptions.
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